All In Biotech

NDA 022037 · Takeda Pharms USA

Intuniv

Guanfacine Hydrochloride · Oral

Last checked: Nov 20, 2026Latest source record: Dec 27, 2019 (newest FDA action)Source: Drugs@FDA, openFDA, CMS, ClinicalTrials.gov, PubMedMethods & limitations

First approved

2009

Sep 2, 2009

Approved uses

5

Original approval plus efficacy supplements

Registered trials

85

15 Phase 3, 8 recruiting

FAERS reports

7,123

4,202 serious, 218 with death reported

AI brief across all sources

Written by AI from the FDA, CMS, ClinicalTrials.gov, FAERS and PubMed data on this page, plus web searches for pricing, exclusivity and pending FDA decisions.

What it is approved for

From the label in effect Jun 23, 2025.

INTUNIV ® is indicated for the treatment of Attention Deficit Hyperactivity Disorder (ADHD) as monotherapy and as adjunctive therapy to stimulant medications [see Clinical Studies (14) ]. INTUNIV is a central alpha 2A -adrenergic receptor agonist indicated for the treatment of Attention Deficit Hyperactivity Disorder (ADHD) as monotherapy and as adjunctive therapy to stimulant medications ( 1 , 14 ).

Mechanism: Guanfacine is a central alpha 2A -adrenergic receptor agonist. Guanfacine is not a central nervous system (CNS) stimulant. The mechanism of action of guanfacine in ADHD is not known.

Approval history

Original approval and efficacy supplements (new uses, populations or doses), newest first, with FDA's letters and labels.

4 products under this application
  • INTUNIV · GUANFACINE HYDROCHLORIDE EQ 3MG BASE · TABLET, EXTENDED RELEASE, ORAL · Prescription · TE AB
  • INTUNIV · GUANFACINE HYDROCHLORIDE EQ 1MG BASE · TABLET, EXTENDED RELEASE, ORAL · Prescription · TE AB
  • INTUNIV · GUANFACINE HYDROCHLORIDE EQ 4MG BASE · TABLET, EXTENDED RELEASE, ORAL · Prescription · TE AB
  • INTUNIV · GUANFACINE HYDROCHLORIDE EQ 2MG BASE · TABLET, EXTENDED RELEASE, ORAL · Prescription · TE AB

Clinical trials

Interventional ClinicalTrials.gov studies with "Guanfacine" as an intervention, any sponsor and status, largest first.

All 85 trials

Most reported adverse reactions

FAERS reports naming this application or brand. Unverified reports, not rates; a report can name several drugs.

Signals
  • drug ineffective740
  • off label use588
  • somnolence433
  • aggression362
  • fatigue311
  • hypotension277
  • dizziness264
  • headache255
  • intentional overdose252
  • suicidal ideation252
  • insomnia250
  • anxiety248

FAERS reports by year

By the date FDA received the report.

View as table
YearReports
20051
20064
20073
20081
200910
2010101
2011202
2012178
2013201
2014315
2015486
2016457
2017467
2018468
2019476
2020473
2021485
2022537
2023586
2024604
2025536
2026532

Recalls

0 FDA enforcement reports for this application.

No recalls on record for this application.

Shortages

FDA's drug shortage list.

Not on FDA's shortage list.

Medicare spending

CMS Spending by Drug. Part D is pharmacy-dispensed; Part B is given in a clinic or hospital outpatient setting. Spending is before manufacturer rebates.

Compare

Part D: Intuniv (Guanfacine HCl)

2024 spending

$209K

Beneficiaries

69

426 claims

Per beneficiary

$3,026

$9.95 per unit

View as table
YearSpending
2020$185,841
2021$203,202
2022$205,381
2023$228,107
2024$208,791

Published evidence

PubMed clinical trials, meta-analyses and systematic reviews, most relevant first.

All 235 on PubMed

Sponsor: Takeda

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.